Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

14.82
+0.37002.56%
Post-market: 14.80-0.0200-0.13%19:59 EDT
Volume:29.34M
Turnover:432.83M
Market Cap:6.71B
PE:-21.00
High:15.11
Open:14.65
Low:14.10
Close:14.45
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.12
T/O Rate:7.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:9.12
PE(LYR):-13.55

Loading ...

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock is Tumbling.

Dow Jones
·
Aug 08

Iovance Biotherapeutics is Maintained at Market Outperform by Citizens

Dow Jones
·
Aug 07

Iovance Biotherapeutics price target raised to $8 from $5 at Citizens

TIPRANKS
·
Aug 07

Iovance Biotherapeutics price target raised to $13 from $11 at Barclays

TIPRANKS
·
Aug 07

Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Aug 07

US FDA Approves Replimune's Skin Cancer Drug

Reuters
·
Aug 07

Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results

Benzinga Earnings
·
Aug 07

U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International

Reuters
·
Aug 07

Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Aug 06

Iovance Biotherapeutics up over 37%, on Pace for Largest Percent Increase Since June 2016

Dow Jones
·
Aug 06

Iovance Biotherapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Iovance Publishes Corporate Presentation Highlighting Amtagvi TIL Therapy Rollout and Pipeline Expansion in Solid Tumors

Reuters
·
Aug 06

Iovance Gains After Q2 Revenue Beat

Reuters
·
Aug 06

Iovance Q2 2026 Earnings: Amtagvi Drives 66% Revenue Growth and a Narrower Loss

TradingKey
·
Aug 06

Earnings Flash (IOVA) Iovance Biotherapeutics Posts Q2 Loss $0.11 a Share, vs. FactSet Est of $0.13 Loss

MT Newswires Live
·
Aug 06

Iovance Biotherapeutics Shares Rise 13.4% Premarket After Q2 Revenue Beat

THOMSON REUTERS
·
Aug 06

Iovance Q2 Operating Loss Narrows to $51.91 Million; Revenue Rises 66% Year over Year to $99.31 Million

Reuters
·
Aug 06

Iovance Biotherapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $99.313M Beat $87.832M Estimate

Benzinga Earnings
·
Aug 06

Iovance Biotherapeutics - Reviewing Fy2026 Revenue Guidance of $350 Mln to $370 Mln

THOMSON REUTERS
·
Aug 06

Iovance Biotherapeutics Q2 Revenue USD 99.313 Million

THOMSON REUTERS
·
Aug 06